Τίτλος:
Experimental isolation and transplantation of hepatocytes with the use
of antibody against interleukin-2 receptor (Daclizumab) as
immunosuppressive agent
Γλώσσες Τεκμηρίου:
Αγγλικά
Περίληψη:
Introduction. Daclizumab (Dmab) is a genetically engineered humanized
IgG1 monoclonal antibody that binds to the a chain of the interleukin-2
receptor (Tac, CD25, p55) expressed on activated human T lymphocytes.
Dmab has been used in a clinical protocol of islet transplantation with
satisfactory results. The aim of the present study was to evaluate the
use of an antibody against the interleukin-2 receptor (Dmab) as an
immunosuppressive agent in an experimental model of hepatocyte
allotransplantation (allo-Tx) in rats with fulminant hepatic failure
(FHF).
Materials and methods. Six Wistar rats were used as donors and 48 Lewis
rats as recipients: four groups of 12 animals each with induction of FHF
and 24 hour later hepatocyte Tx-group A: no treatment; group B:
cyclosporin (20 mg/kg days 0 to 5 and 10 mg/kg days 6 to 15); group C:
Dmab (0.05 mg day of Tx and 0.05 mg day 7); and group D: Dmab and
cyclosporine. Hepatocytes were transplanted intrasplenically. Animals
were followed for 15 days.
Results. Statistical analysis showed better survival among groups C
(83%, MST = 13) and D (92%, MST = 14.25) compared to groups A (max 72,
MST = 1.5) or B (50%, MST = 9). Survival in group D was better but not
significantly than group C. Biochemical evaluation and histology
confirmed satisfactory function and engraftment, respectively.
Conclusion. This experimental model showed the safe, effective use of
Dmab.
Συγγραφείς:
Tsiolis, I
Papalois, A
Loukopoulos, I
Gravvanis, A and
Lykoudis, E
Theodossopoulou, E
Chairakakis, A and
Dimitroulopoulos, D
Sfiniadakis, I
Vassiliou, I
Felekouras,
E
Dedeilias, P
Kontogiorgi, M
Papadimitrou, L and
Papadimitriou, I
Περιοδικό:
Transplantation Proceedings
Εκδότης:
EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
DOI:
10.1016/j.transproceed.2005.02.097
